Tumour Angiogenesis
Why we focus on Angiogenesis
Angiogenesis is the formation of new blood vessels from pre-existing ones and is essential for cancer progression and metastasis. Manipulating tumour angiogenesis could stop cancer growth and spread. Understanding the cellular and molecular basis of tumour angiogenesis will lead us to novel and improved ways to control cancer.
What we do
- We aim to improve the understanding of the molecular regulation of tumour angiogenesis.
- Since angiogenesis is a feature of all solid cancers, it is crucial that we unravel both the molecular and cellular basis of this process.
- Our work provides essential insights into the critical functions of growth factor receptors, adhesion molecules and cytokines in the control of tumour angiogenesis in various cancer models.
- Importantly, we have discovered novel targets for angiogenic therapy that we aim will, one day, improve the treatment of human cancer.
Key Publications
- Reynolds et al. Enhanced pathological angiogenesis in mice lacking β3-integrin or β3- and β5-integrins. Nature Medicine 2002; 8: 27-34.
- Reynolds et al. Stimulation of tumor growth and angiogenesis by low concentrations of integrin inhibitors in therapy-resistant tumors. Nature Medicine 2009; 15: 392-400.
- Reynolds et al. Tumour angiogenesis is reduced in the Tc1 mouse model of Down’s syndrome. Nature 2010; 465: 813-817.
- Graupera et al. Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration. Nature 2008; 453: 662-666.
- Hagemann et al. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther. 2007; 6: 1993-2002.
Who does the research
→ Click here for BCI senior researchers working on angiogenesis.
Major Funders
- BBSRC
- Breast Cancer Campaign
- Cancer Research UK
- EU
- Medical Research Council
- Ovarian Cancer Action
- Pancreatic Cancer Research Fund
